bioAffinity Technologies, Inc. (BIAF)
About bioAffinity Technologies, Inc.
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $6.2M
- Net income
- -$14.9M
- Total assets
- $11.0M
- Market cap
- $7.8M
- Operating margin
- -171.6%
- Net margin
- -242.0%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $6.2M
- Operating expenses
- $16.7M
- Operating income
- -$10.6M
- Income tax
- $44.0K
- Net income
- -$14.9M
- EPS (basic)
- $-8.66
- EPS (diluted)
- $-8.66
Balance sheet
- Total assets
- $11.0M
- Current assets
- $7.6M
- Total liabilities
- $3.7M
- Current liabilities
- $2.9M
- Shareholders’ equity
- $7.3M
Cash flow
- Operating cash flow
- -$9.3M
- Investing cash flow
- -$60.6K
- Financing cash flow
- $14.7M
- Net cash flow
- $5.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $7.8M
- EPS (diluted)
- $-8.66
- Shares outstanding
- 11.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 1, 2022
bioAffinity Technologies, Inc. (BIAF) Stock Price
- Reported a net loss of $14.9M in FY2025.
- Revenue grew 142012% from FY2022 to FY2025.
- Trading 94% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review bioAffinity Technologies, Inc..
Write a review
News about bioAffinity Technologies, Inc.
News & sentiment via Polygon.io
bioAffinity Technologies, Inc.: frequently asked questions
Is bioAffinity Technologies, Inc. an American company?
bioAffinity Technologies, Inc. is a US-based company headquartered in San Antonio, Texas, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is bioAffinity Technologies, Inc. headquartered?
bioAffinity Technologies, Inc. is headquartered in San Antonio, Texas, United States.
Is bioAffinity Technologies, Inc. publicly traded?
Yes — bioAffinity Technologies, Inc. is a publicly traded company. Its stock trades under the ticker symbol BIAF on the NASDAQ.
What does bioAffinity Technologies, Inc. do?
bioAffinity Technologies, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
